Craig Austin, MD
Dermatology · Fishkill, NYNPI 1225149982
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.9% of the total across 210 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,000 and has fallen 52.6% since, to $475 in 2025.
Across 210 payments — averaging $20.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$875
- AbbVie$786
- Merz North America, Inc.$432
- Incyte Corporation$327
- Johnson & Johnson$315
- Amgen$253
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,15295%
- Education$2225%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 45 | $875 |
| AbbVie(2 entities) | 50 | $786 |
| Merz North America, Inc. | 4 | $432 |
| Incyte Corporation | 16 | $327 |
| Johnson & Johnson | 14 | $315 |
| Amgen | 13 | $253 |
| LEO Pharma Inc. | 11 | $242 |
| Sanofi | 8 | $190 |
| E.r. Squibb & Sons, L.L.C. | 8 | $178 |
| Lilly USA, LLC | 6 | $118 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 7 | $109 |
| UCB, Inc. | 3 | $79 |
| Arcutis Biotherapeutics, Inc. | 3 | $58 |
| Bristol Myers Squibb | 3 | $57 |
| Galderma Laboratories, L.p. | 3 | $47 |
| Dermavant Sciences, Inc. | 2 | $39 |
| VYNE Pharmaceuticals Inc. | 2 | $38 |
| Almirall LLC | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Sun Pharmaceutical Industries Inc. | 1 | $27 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Biofrontera Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Botanix SB Inc | 1 | $19 |
| Novartis | 1 | $18 |
| Krystal Biotech Inc | 1 | $16 |
| Mayne Pharma Commercial LLC | 1 | $15 |
| Organon | 1 | $5 |
How this compares
$4,374 in reported general payments places this provider in the 60th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpzeluraRuxolitinib Phosphate | 16 | $31,542 |
| Desonide | 46 | $3,638 |
| Fluticasone Propionate | 89 | $2,799 |
| Ammonium Lactate | 122 | $2,447 |
| Tacrolimus | 26 | $2,177 |
| Clobetasol Propionate | 37 | $1,956 |
| Econazole Nitrate | 91 | $1,878 |
| Metronidazole | 32 | $1,824 |
| Ketoconazole | 92 | $1,722 |
| Fluocinolone Acetonide | 41 | $1,491 |
| Ciclopirox | 40 | $1,479 |
| Tretinoin | 19 | $1,233 |
| Triamcinolone Acetonide | 71 | $1,097 |
| CiclopiroxCiclopirox Olamine | 13 | $661 |
| Fluorouracil | 13 | $624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $327 | $31,54216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,151 dermatology providers in New York.
Other dermatology in Fishkill
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Jeffrey WeinbergKew Gardens$2.3M
- Joshua ZeichnerNew York$2.1M
- Russell CohenOceanside$2.1M
- Jeffrey LaducaAuburn$1.9M
- Emma GuttmanNew York$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.